Activation of Nrf2 and Hypoxic Adaptive Response Contribute to Neuroprotection Elicited by Phenylhydroxamic Acid Selective HDAC6 Inhibitors
- 17 January 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 9 (5) , 894-900
Abstract
Activation of HIF-1α and Nrf2 is a primary component of cellular response to oxidative stress, and activation of HIF-1α and Nrf2 provides neuroprotection in models of neurodegenerative disorders, including ischemic stroke, Alzheimer’s and Parkinson’s diseases. Screening a library of CNS-targeted drugs using novel reporters for HIF-1α and Nrf2 elevation in neuronal cells revealed histone deacetylase (HDAC) inhibitors as potential activators of these pathways. We report the identification of phenylhydroxamates as single agents exhibiting tripartite inhibition of HDAC6, inhibition of HIF-1 prolyl hydroxylase (PHD), and activation of Nrf2. Two superior tripartite agents, ING-6 and ING-66, showed neuroprotection against various cellular insults, associated with stabilization of both Nrf2 and HIF-1, and expression of their respective target genes in vitro and in vivo. Discovery of the innate ability of phenylhydroxamate HDAC inhibitors to activate Nrf2 and HIF provides a novel route to multifunctional neuroprotective agents and cautions against HDAC6 selective inhibitors as chemical probes of specific HDAC isoform function.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (NS079183, R01 NS060885, NS101967)
- International Rett Syndrome Foundation (2769)
- Russian Science Foundation (16-14-10226)
- National Parkinson Foundation
- Thomas Hartman Foundation for Parkinson?s Research
- Michael J. Fox Foundation for Parkinson's Research
- Par Fore Parkinsons Inc.
- Winifred Masterson Burke Foundation, Inc.
This publication has 29 references indexed in Scilit:
- Activated microglia decrease histone acetylation and Nrf2-inducible anti-oxidant defence in astrocytes: Restoring effects of inhibitors of HDACs, p38 MAPK and GSK3βNeurobiology of Disease, 2011
- Development of Neh2-Luciferase Reporter and Its Application for High Throughput Screening and Real-Time Monitoring of Nrf2 ActivatorsChemistry & Biology, 2011
- When NRF2 Talks, Who's Listening?Antioxidants & Redox Signaling, 2010
- Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin AJournal of the American Chemical Society, 2010
- Utilization of an In Vivo Reporter for High Throughput Identification of Branched Small Molecule Regulators of Hypoxic AdaptationChemistry & Biology, 2010
- Selective Inhibition of Hypoxia-Inducible Factor (HIF) Prolyl-Hydroxylase 1 Mediates Neuroprotection against Normoxic Oxidative Death via HIF- and CREB-Independent PathwaysJournal of Neuroscience, 2009
- Acetylation of Nrf2 by p300/CBP Augments Promoter-Specific DNA Binding of Nrf2 during the Antioxidant ResponseMolecular and Cellular Biology, 2009
- The Nrf2/ARE Pathway as a Potential Therapeutic Target in Neurodegenerative DiseaseAntioxidants & Redox Signaling, 2009
- Specific inhibition of hypoxia inducible factor 1 exaggerates cell injury induced by in vitro ischemia through deteriorating cellular redox environmentJournal of Neurochemistry, 2009
- Novel inhibitors of prolyl 4-hydroxylase. 5. The intriguing structure-activity relationships seen with 2,2'-bipyridine and its 5,5'-dicarboxylic acid derivativesJournal of Medicinal Chemistry, 1993